{"id":419626,"date":"2021-01-22T12:17:36","date_gmt":"2021-01-22T17:17:36","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=419626"},"modified":"2021-01-22T12:17:36","modified_gmt":"2021-01-22T17:17:36","slug":"algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\/","title":{"rendered":"Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">VANCOUVER, British Columbia, Jan.  22, 2021  (GLOBE NEWSWIRE) &#8212; Algernon Pharmaceuticals Inc.\u00a0(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the \u201cCompany\u201d or \u201cAlgernon\u201d) a clinical stage pharmaceutical development company is pleased to provide a final summary of the common share purchase warrants of the Company (the \u201cNovember\u00a0Warrants\u201d), that were issued on November 1, 2019.<\/p>\n<p align=\"justify\">The Company elected to exercise its acceleration right under the warrant indenture (the \u201cIndenture\u201d) governing the November\u00a0Warrants. Pursuant to the terms of the Indenture, the Company accelerated the expiry date of the November Warrants when the daily volume-weighted average trading price of the common shares of the Company exceeded CDN$0.35 for the preceding 20 consecutive trading days on the Canadian Securities Exchange (the \u201cCSE\u201d). The accelerated warrant expiry date was set for January 21, 2021.<\/p>\n<p align=\"justify\">The Company announces that as of close of market on January 21, 2021, approximately 23M November Warrants were exercised since their original date of issue resulting in an additional capital contribution of CDN$2.76M to the Company. Any unexercised November Warrants have now been cancelled. The warrants, trading under the symbol of AGN.WT, were halted by the CSE and have now been delisted.<\/p>\n<p align=\"justify\">\n        <strong>About Algernon Pharmaceuticals Inc.\u00a0<\/strong>\n      <\/p>\n<p align=\"justify\">Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.<\/p>\n<p align=\"justify\">\n        <strong>CONTACT INFORMATION<\/strong>\n      <\/p>\n<p align=\"justify\">Christopher J. Moreau<\/p>\n<p>CEO<br \/>Algernon Pharmaceuticals Inc.<br \/>604.398.4175 ext 701<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gbF3SgSm64dYVeyCpcg-bBTW-QJwqZJ5mcQOQyP1srUvjXQo3IzF1YxGQFBo7psW4vVpKyv3pTJl_b0A5slthWoY6vvJpbTC1NGws10eHvT1eTeydVajbBvxOB4Iwsx4\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">info@algernonpharmaceuticals.com<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LdSC7oiL3rdEt-mZnquHpJ6SKiiNLklXXlgQOFnnOmh1CxhNRoe5Riiw3HWDpSCF_XVdynZsdBf4oNROMQt3dA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uOnKptL7jk11FPIWm9s-ea5mXZ-NbQvlGjbYz_xlSlnilebHShn44OtYlrZdLQT-a-atFjgPGS1Aj1rUfWJIZYJ3ZnItRCO8dRtIjjvTDkGsG-hocXK-qVRELecP0lrP\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">investors@algernonpharmaceuticals<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=s-LN4lWNG7RCCc6_PJdBv6Rp62KeaVeKbHLyUBikALjcvipc_Mefj2fbQjG3k-NE_QY0uyR0xRNJHNJCGbCBrkoe1PDomz1ub1pLOVFCGBE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">.com<br \/><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Fco-qeZnqv-HMctNTIb0IavQotHvmQJ7IrZXTrmHMIiIAtr2StIXX2mO-DxGA8RNhx07qjyCsvlLObBWcxID1PoeUvgfayuRD9MgGwuXhhTk7rZbxb4NT0BhwWfAEOJf\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.algernonpharmaceuticals.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as \u201cwill\u201d, \u201cmay\u201d, \u201cshould\u201d, \u201canticipate\u201d, \u201cexpects\u201d and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company\u2019s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.<\/em>\n      <\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDI0NyMzOTQxMTM5IzIwOTIzNjc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/f660720a-190f-4016-9a4e-aacaf605c9d8\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>VANCOUVER, British Columbia, Jan. 22, 2021 (GLOBE NEWSWIRE) &#8212; Algernon Pharmaceuticals Inc.\u00a0(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the \u201cCompany\u201d or \u201cAlgernon\u201d) a clinical stage pharmaceutical development company is pleased to provide a final summary of the common share purchase warrants of the Company (the \u201cNovember\u00a0Warrants\u201d), that were issued on November 1, 2019. The Company elected to exercise its acceleration right under the warrant indenture (the \u201cIndenture\u201d) governing the November\u00a0Warrants. Pursuant to the terms of the Indenture, the Company accelerated the expiry date of the November Warrants when the daily volume-weighted average trading price of the common shares of the Company exceeded CDN$0.35 for the preceding 20 consecutive trading days on the Canadian Securities Exchange (the \u201cCSE\u201d). The accelerated warrant expiry &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-419626","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"VANCOUVER, British Columbia, Jan. 22, 2021 (GLOBE NEWSWIRE) &#8212; Algernon Pharmaceuticals Inc.\u00a0(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the \u201cCompany\u201d or \u201cAlgernon\u201d) a clinical stage pharmaceutical development company is pleased to provide a final summary of the common share purchase warrants of the Company (the \u201cNovember\u00a0Warrants\u201d), that were issued on November 1, 2019. The Company elected to exercise its acceleration right under the warrant indenture (the \u201cIndenture\u201d) governing the November\u00a0Warrants. Pursuant to the terms of the Indenture, the Company accelerated the expiry date of the November Warrants when the daily volume-weighted average trading price of the common shares of the Company exceeded CDN$0.35 for the preceding 20 consecutive trading days on the Canadian Securities Exchange (the \u201cCSE\u201d). The accelerated warrant expiry &hellip; Continue reading &quot;Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-22T17:17:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDI0NyMzOTQxMTM5IzIwOTIzNjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants\",\"datePublished\":\"2021-01-22T17:17:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\\\/\"},\"wordCount\":637,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MDI0NyMzOTQxMTM5IzIwOTIzNjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\\\/\",\"name\":\"Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MDI0NyMzOTQxMTM5IzIwOTIzNjc=\",\"datePublished\":\"2021-01-22T17:17:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MDI0NyMzOTQxMTM5IzIwOTIzNjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MDI0NyMzOTQxMTM5IzIwOTIzNjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\/","og_locale":"en_US","og_type":"article","og_title":"Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants - Market Newsdesk","og_description":"VANCOUVER, British Columbia, Jan. 22, 2021 (GLOBE NEWSWIRE) &#8212; Algernon Pharmaceuticals Inc.\u00a0(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the \u201cCompany\u201d or \u201cAlgernon\u201d) a clinical stage pharmaceutical development company is pleased to provide a final summary of the common share purchase warrants of the Company (the \u201cNovember\u00a0Warrants\u201d), that were issued on November 1, 2019. The Company elected to exercise its acceleration right under the warrant indenture (the \u201cIndenture\u201d) governing the November\u00a0Warrants. Pursuant to the terms of the Indenture, the Company accelerated the expiry date of the November Warrants when the daily volume-weighted average trading price of the common shares of the Company exceeded CDN$0.35 for the preceding 20 consecutive trading days on the Canadian Securities Exchange (the \u201cCSE\u201d). The accelerated warrant expiry &hellip; Continue reading \"Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-22T17:17:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDI0NyMzOTQxMTM5IzIwOTIzNjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants","datePublished":"2021-01-22T17:17:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\/"},"wordCount":637,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDI0NyMzOTQxMTM5IzIwOTIzNjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\/","name":"Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDI0NyMzOTQxMTM5IzIwOTIzNjc=","datePublished":"2021-01-22T17:17:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDI0NyMzOTQxMTM5IzIwOTIzNjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDI0NyMzOTQxMTM5IzIwOTIzNjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-pharmaceuticals-provides-final-summary-on-accelerated-warrants\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/419626","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=419626"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/419626\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=419626"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=419626"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=419626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}